- Home
- QURE vs PHAT Comparison
QURE vs PHAT Comparison
Compare QURE & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QURE
- PHAT
- Stock Information
- Founded
- QURE 1998
- PHAT 2018
- Country
- QURE Netherlands
- PHAT United States
- Employees
- QURE N/A
- PHAT N/A
- Industry
- QURE Biotechnology: Pharmaceutical Preparations
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- QURE Health Care
- PHAT Health Care
- Exchange
- QURE Nasdaq
- PHAT Nasdaq
- Market Cap
- QURE 866.3M
- PHAT 820.8M
- IPO Year
- QURE 2007
- PHAT 2019
- Fundamental
- Price
- QURE $14.16
- PHAT $11.00
- Analyst Decision
- QURE Strong Buy
- PHAT Strong Buy
- Analyst Count
- QURE 11
- PHAT 5
- Target Price
- QURE $39.91
- PHAT $16.40
- AVG Volume (30 Days)
- QURE 1.1M
- PHAT 1.0M
- Earning Date
- QURE 11-04-2025
- PHAT 11-06-2025
- Dividend Yield
- QURE N/A
- PHAT N/A
- EPS Growth
- QURE N/A
- PHAT N/A
- EPS
- QURE N/A
- PHAT N/A
- Revenue
- QURE $14,337,000.00
- PHAT $114,039,000.00
- Revenue This Year
- QURE N/A
- PHAT $207.52
- Revenue Next Year
- QURE $288.08
- PHAT $96.46
- P/E Ratio
- QURE N/A
- PHAT N/A
- Revenue Growth
- QURE N/A
- PHAT 1049.82
- 52 Week Low
- QURE $4.45
- PHAT $2.21
- 52 Week High
- QURE $19.18
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- QURE 34.28
- PHAT 46.33
- Support Level
- QURE $17.03
- PHAT $10.84
- Resistance Level
- QURE $17.76
- PHAT $13.00
- Average True Range (ATR)
- QURE 0.95
- PHAT 0.67
- MACD
- QURE -0.39
- PHAT -0.25
- Stochastic Oscillator
- QURE 3.13
- PHAT 7.41
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.